Weiwei Dai

Weiwei Dai received his B.S. in Biotechnology from Northwest University, Xi’an (2008), M.Sc. in Fish Nutrition from Ocean University of China, Qingdao (2011), and Ph.D. in Institut National de la Recherche Agronomique (INRA), France (2016). During 2016 and 2023, Dr. Dai continued his academic career in United States as a postdoctoral fellow at The Pennsylvania State University (2016-2018) and a Post-Doctoral Associate at Rutgers University (2018-2023). Dr. Dai joined the Department of Biosciences and Bioinformatics at XJTLU as an assistant professor in June, 2023, and serves as the Director of Suzhou Municipal Key Lab for Metabolic Syndrome Drug Research since June, 2024. Dr. Dai's research has been mainly focused on studying Nutrition and Metabolism in liver and metabolic diseases including obesity and liver cancer. Currently, he is focusing on studying cancer metabolism, especially amino acid/nitrogen metabolism in liver cancer, as well as epigenetic regulation on metabolic enzymes in liver tumor microenvironments. Dr. Dai has published 17 peer-reviewed papers, including 8 first-author SCI research articles, such as J Clin Invest (IF=19.5), The FASEB Journal, JMCB, BBA Mol Basis Dis., and 2 second-author articles; as well as 2 first-author patents for invention. Dr. Dai is funded by the National Natural Science Foundation of China general project (2025-2028) as the Principal investigator. Dr. Dai also actively serves in the academic community as a member of Chinese Society for Cell Biology and The Chinese Society of Biochemistry and Molecular Biology, as well as journal reviewers for Journal of Molecular Cell Biology (IF=8.19), Clinical Science (IF=5.22), Frontiers in Nutrition (IF=5), and Bioscience Reports.

代伟伟本科毕业于西北大学生物技术专业（2008）；硕士毕业于中国海洋大学（2011），师从麦康森院士和艾庆辉教授（“国家杰青”、“长江学者”）；博士毕业于法国国家农业科学研究院（INRA，2016）。2016-2023年期间先后在美国宾夕法尼亚州立大学和罗格斯大学从事博士后研究。目前代博士担任苏州市代谢综合征和新药研发重点实验室主任，西交利物大学理学院副研究员。过去数十年代博士一直从事肝脏营养和代谢研究，目前的主要研究方向为肿瘤代谢与氨基酸/氮代谢。近几年以第一作者在J Clin Invest (IF=19.5)，The FASEB Journal，JMCB，BBA Mol Basis Dis.等经典SCI杂志发表科研文章11篇；共同作者文章7篇；第一发明人发明专利2项; 主持国家自然科学基金面上项目一项（2025-2028）。中国细胞生物学学会、中国生物物理学会、中国生物化学与分子生物学、中国营养学会和苏州市生物学会会员。同时担任Journal of Molecular Cell Biology, Clinical Science、Frontiers in Nutrition, Bioscience Reports 和Aquaculture等杂志的审稿人。

Dr. Dai's recent research talk on CST webinars can be accessed below:https://learn.cellsignal.cn/cn-online-seminar 代博士近期在CST博士云讲座的报告“谷氨酰胺合成酶通过调节氮代谢和抑制mTORC1活性限制肝肿瘤生长”可以通过以下链接观看：https://learn.cellsignal.cn/cn-online-seminar

Dr. Dai Webpage: https://connect.xjtlu.edu.cn/user/weiwei-dai    

Dai Lab: https://connect.xjtlu.edu.cn/group/dai-lab-bio-department  

Suzhou Key Lab: https://connect.xjtlu.edu.cn/group/suzhou-key-lab-in-metabolic-di

We highly welcome self-motivated PhD candidates, master students, Y4 FYP students, and/or Y2&3 volunteers to join our Dai Lab family. If interested, please don't hesitate to visit Dr. Dai in SA457, or contact via emal (Weiwei.Dai@xjtlu.edu.cn) or WeChat (18862120238).